SCHEMBL542090

SCHEMBL542090

CC(N(CCO)CCO)S(=O)(=O)O

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11143949 0.89 FDPS (0.31)
SCHEMBL11149077 0.86
SCHEMBL11142133 0.86
SCHEMBL11145698 0.85 LMNA (0.40) MEN1KMT2AALDH1A1
SCHEMBL11141039 0.85 LMNA (0.40) MEN1KMT2AALDH1A1
SCHEMBL7621772 0.82
SCHEMBL7622756 0.81 MAPT (0.32) MAPT
SCHEMBL27992827 0.80
SCHEMBL11146990 0.79 MEN1 (0.32) MAPTMEN1KMT2A
SCHEMBL11143689 0.79 MAPT (0.36) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939938-B2 Amphiphilic cationic associative polymers, preparation process, use as thickeners and composition comprising them L'OREAL S.A. (FR) 2005-09-06 US claimed
US-20030166822-A1 Amphiphilic cationic associative polymers, preparation process, use as thickeners and composition comprising them L'OREAL S.A. (FR) 2003-09-04 US claimed
EP-0592242-B1 Fibrin sealant compositions and method for utilizing same SQUIBB & SONS INC (US) 2003-07-09 EP claimed
US-5750657-A Methods and compositions using fibrin monomer to make a fibrin sealant BRISTOL-MYERS SQUIBB COMPANY (US) 1998-05-12 US claimed
EP-0592242-A1 Fibrin sealant compositions and method for utilizing same E.R. SQUIBB & SONS, INC. (US) 1994-04-13 EP claimed
US-4322324-A Ampho-ionic group-containing alkyd resins NIPPON PAINT CO., LTD. (JP) 1982-03-30 US claimed
JP-2000630-A None JP disclosed
JP-8009996-A None JP disclosed
EP-4262689-B1 COMPOSITION COMPRISING A PARTICULAR OXIDATION DYEING BASE, AT LEAST ONE GUAR GUM AND AT LEAST ONE FATTY SUBSTANCE OREAL (FR) 2026-04-08 EP disclosed
EP-4240311-B1 COMPOSITION FOR KERATIN FIBERS OREAL (FR) 2026-04-01 EP disclosed
US-20260035593-A1 AQUEOUS COATING MATERIAL COMPOSITION, METHOD FOR FORMING COATING FILM, AND METHOD FOR FORMING MULTILAYER COATING FILM KANSAI PAINT CO LTD (JP) 2026-02-05 US disclosed
US-20260000590-A1 COSMETIC HAIR TREATMENT PROCESS, COMPRISING A WASHING STEP, A STEP OF APPLYING A COSMETIC COMPOSITION COMPRISING AMINO ACIDS AND HYDROXYLATED (POLY)CARBOXYLIC ACIDS, AND THEN A CONDITIONING STEP OREAL (FR) 2026-01-01 US disclosed
EP-4452203-B1 PROCESS FOR DYEING KERATIN FIBRES USING A COSMETIC COMPOSITION COMPRISING PROPANE-1,3-DIOL AND A DYEING COMPOSITION OREAL (FR) 2025-12-24 EP disclosed
US-4563291-A Method of preparation of substituted amino-alkyl sulfonic acid compounds and use in the treatment of subterranean formations HALLIBURTON COMPANY (US) 1986-01-07 US disclosed
US-4554251-A PSEUDOMYREMEX TRIPLARINUS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1985-11-19 US disclosed
US-4530946-A Crosslinked copolymer of ethylically unsaturated monomer NIPPON PAINT CO., LTD. (JP) 1985-07-23 US disclosed
EP-0141182-A2 Process and medium for culturing ant venom gland cells THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1985-05-15 EP disclosed
US-4368287-A POLYESTER CONTAINING AMINO-SULFONIC AMPHOIONIC GROUP NIPPON PAINT CO., LTD. (JP) 1983-01-11 US disclosed
US-4328143-A Aqueous coating composition NIPPON PAINT COMPANY, LTD. (JP) 1982-05-04 US disclosed
US-4322324-A Ampho-ionic group-containing alkyd resins NIPPON PAINT CO., LTD. (JP) 1982-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260000590-A1 COSMETIC HAIR TREATMENT PROCESS, COMPRISING A WASHING STEP, A STEP OF APPLYING A COSMETIC COMPOSITION COMPRISING AMINO ACIDS AND HYDROXYLATED (POLY)CARBOXYLIC ACIDS, AND THEN A CONDITIONING STEP HRH3, HRH1, H1-2 MAPT 4738/4885MEN1 1385/4885KMT2A 1750/4885
US-20260035593-A1 AQUEOUS COATING MATERIAL COMPOSITION, METHOD FOR FORMING COATING FILM, AND METHOD FOR FORMING MULTILAYER COATING FILM COL2A1, ALKBH2, C9 MAPT 404/4885MEN1 942/4885KMT2A 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.